GI side effects like nausea and diarrhea were most common, but these were manageable and resolved over time, researchers said.No increase in serious adverse events or severe low blood sugar was seen with the higher dose.The greater magnitudes of bodyweight reduction seen in this trial, as well as the improvements in cardiovascular risk factors and glucose control, can have beneficial effects on health goals in clinical practice, researchers concluded.However, they noted that further research is needed to fully understand the long-term benefits and risks of a tripled semaglutide dose taken regularly.Novo Nordisk, the maker of semaglutide, sponsored both clinical trials.More informationThe University of California-Davis has more on semaglutide for weight loss.SOURCES: The Lancet, news release, Sept
This material is supplied strictly for qualified laboratory research
no FDA endorsement exists for therapeutic claims
General Procedure for Peptide Coupling Synthesis of (S,S) Di-Tert-Butyl (5-(Tert-Butoxy)-4-((Tert-Butoxycarbonyl)Amino)-5-Oxopentanoyl)Glutamate 1 ( S )Boc-Glu-O t Bu (1 mmol, 303.4 mg), ( S )HCl,H-Glu(O t Bu)-O t Bu (1 mmol, 295.8 mg), BOP (1.2 mmol, 530.7 mg), and DIEA (3 mmol, 0.52 ml, pH = 8.5) were dissolved in THF (15 ml) and stirred at room temperature
Quantitative flux analysis reveals folate-dependent NADPH production